Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1

Kong, Leopold; Giang, Erick; Robbins, Justin B; Stanfield, Robyn L; Burton, Dennis R; Wilson, Ian A; Law, Mansun

doi:10.1073/pnas.1202924109

Title: Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1

Full Record
Other Related Research

Abstract

Hepatitis C virus (HCV) infects more than 2% of the global population and is a leading cause of liver cirrhosis, hepatocellular carcinoma, and end-stage liver diseases. Circulating HCV is genetically diverse, and therefore a broadly effective vaccine must target conserved T- and B-cell epitopes of the virus. Human mAb HCV1 has broad neutralizing activity against HCV isolates from at least four major genotypes and protects in the chimpanzee model from primary HCV challenge. The antibody targets a conserved antigenic site (residues 412-423) on the virus E2 envelope glycoprotein. Two crystal structures of HCV1 Fab in complex with an epitope peptide at 1.8-{angstrom} resolution reveal that the epitope is a {beta}-hairpin displaying a hydrophilic face and a hydrophobic face on opposing sides of the hairpin. The antibody predominantly interacts with E2 residues Leu{sup 413} and Trp{sup 420} on the hydrophobic face of the epitope, thus providing an explanation for how HCV isolates bearing mutations at Asn{sup 415} on the same binding face escape neutralization by this antibody. The results provide structural information for a neutralizing epitope on the HCV E2 glycoprotein and should help guide rational design of HCV immunogens to elicit similar broadly neutralizing antibodies through vaccination.

Authors:

Kong, Leopold; Giang, Erick; Robbins, Justin B; Stanfield, Robyn L; Burton, Dennis R; Wilson, Ian A; Law, Mansun ^[1]

Scripps

Publication Date:: Mon Oct 29 00:00:00 EDT 2012

Research Org.:: Argonne National Lab. (ANL), Argonne, IL (United States). Advanced Photon Source (APS)

Sponsoring Org.:: OTHERNIH

OSTI Identifier:: 1046254

Resource Type:: Journal Article

Journal Name:: Proc. Natl. Acad. Sci. USA

Additional Journal Information:: Journal Volume: 109; Journal Issue: (24) ; 06, 2012; Journal ID: ISSN 0027-8424

Country of Publication:: United States

Language:: ENGLISH

Subject:: 60 APPLIED LIFE SCIENCES; ANTIBODIES; CARCINOMAS; CRYSTAL STRUCTURE; HEPATITIS; LIVER; LIVER CIRRHOSIS; VACCINES; VIRUSES

Citation Formats


                    Kong, Leopold, Giang, Erick, Robbins, Justin B, Stanfield, Robyn L, Burton, Dennis R, Wilson, Ian A, and Law, Mansun. Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1.  United States: N. p., 2012. 
        Web.  doi:10.1073/pnas.1202924109.

Copy to clipboard


                    Kong, Leopold, Giang, Erick, Robbins, Justin B, Stanfield, Robyn L, Burton, Dennis R, Wilson, Ian A, & Law, Mansun. Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1.  United States.  https://doi.org/10.1073/pnas.1202924109

Copy to clipboard


                    Kong, Leopold, Giang, Erick, Robbins, Justin B, Stanfield, Robyn L, Burton, Dennis R, Wilson, Ian A, and Law, Mansun. 2012.  
        "Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1".  United States.  https://doi.org/10.1073/pnas.1202924109.

Copy to clipboard


                    
@article{osti_1046254,

  title        = {Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1},

  author       = {Kong, Leopold and Giang, Erick and Robbins, Justin B and Stanfield, Robyn L and Burton, Dennis R and Wilson, Ian A and Law, Mansun},

  abstractNote = {Hepatitis C virus (HCV) infects more than 2% of the global population and is a leading cause of liver cirrhosis, hepatocellular carcinoma, and end-stage liver diseases. Circulating HCV is genetically diverse, and therefore a broadly effective vaccine must target conserved T- and B-cell epitopes of the virus. Human mAb HCV1 has broad neutralizing activity against HCV isolates from at least four major genotypes and protects in the chimpanzee model from primary HCV challenge. The antibody targets a conserved antigenic site (residues 412-423) on the virus E2 envelope glycoprotein. Two crystal structures of HCV1 Fab in complex with an epitope peptide at 1.8-{angstrom} resolution reveal that the epitope is a {beta}-hairpin displaying a hydrophilic face and a hydrophobic face on opposing sides of the hairpin. The antibody predominantly interacts with E2 residues Leu{sup 413} and Trp{sup 420} on the hydrophobic face of the epitope, thus providing an explanation for how HCV isolates bearing mutations at Asn{sup 415} on the same binding face escape neutralization by this antibody. The results provide structural information for a neutralizing epitope on the HCV E2 glycoprotein and should help guide rational design of HCV immunogens to elicit similar broadly neutralizing antibodies through vaccination.},

  doi          = {10.1073/pnas.1202924109},

  url          = {https://www.osti.gov/biblio/1046254},
  journal      = {Proc. Natl. Acad. Sci. USA},

  issn         = {0027-8424},

  number       = (24) ; 06, 2012,

  volume       = 109,

  place        = {United States},

  year         = {Mon Oct 29 00:00:00 EDT 2012},

  month        = {Mon Oct 29 00:00:00 EDT 2012}

}

Copy to clipboard

Journal Article:

https://doi.org/10.1073/pnas.1202924109

Other availability

Find in Google Scholar

Search WorldCat to find libraries that may hold this journal

Save / Share:

Export Metadata

Save to My Library

Similar records in OSTI.GOV collections:

Structure-Based Design of Hepatitis C Virus Vaccines That Elicit Neutralizing Antibody Responses to a Conserved Epitope

Journal Article Pierce, Brian; Boucher, Elisabeth; Piepenbrink, Kurt; ... - Journal of Virology

Despite recent advances in therapeutic options, hepatitis C virus (HCV) remains a severe global disease burden, and a vaccine can substantially reduce its incidence. Due to its extremely high sequence variability, HCV can readily escape the immune response; thus, an effective vaccine must target conserved, functionally important epitopes. Using the structure of a broadly neutralizing antibody in complex with a conserved linear epitope from the HCV E2 envelope glycoprotein (residues 412 to 423; epitope I), we performed structure-based design of immunogens to induce antibody responses to this epitope. This resulted in epitope-based immunogens based on a cyclic defensin protein, asmore »« less
https://doi.org/10.1128/JVI.01032-17
Immunogenetic and structural analysis of a class of HCV broadly neutralizing antibodies and their precursors

Journal Article Aleman, Fernando; Tzarum, Netanel; Kong, Leopold; ... - Proceedings of the National Academy of Sciences of the United States of America

Elicitation of broadly neutralizing antibodies (bnAbs) is a leading strategy in rational vaccine design against antigenically diverse pathogens. Here, we studied a panel of monoclonal antibodies (mAbs) from mice immunized with the hepatitis C virus (HCV) envelope glycoproteins E1E2. Six of the mAbs recognize the conserved E2 antigenic site 412–423 (AS412) and cross-neutralize diverse HCV genotypes. Immunogenetic and structural analysis revealed that the antibodies originated from two different germline (GL) precursors and bind AS412 in a β-hairpin conformation. Intriguingly, the anti-HCV activity of one antibody lineage is associated with maturation of the light chain (LC), whereas the other lineage ismore »« less
Cited by 9
https://doi.org/10.1073/pnas.1802378115

Full Text Available
Hepatitis C Virus E2 Envelope Glycoprotein Core Structure

Journal Article Kong, Leopold; Giang, Erick; Nieusma, Travis; ... - Science

Hepatitis C virus (HCV), a Hepacivirus, is a major cause of viral hepatitis, liver cirrhosis, and hepatocellular carcinoma. HCV envelope glycoproteins E1 and E2 mediate fusion and entry into host cells and are the primary targets of the humoral immune response. The crystal structure of the E2 core bound to broadly neutralizing antibody AR3C at 2.65 angstroms reveals a compact architecture composed of a central immunoglobulin-fold β sandwich flanked by two additional protein layers. The CD81 receptor binding site was identified by electron microscopy and site-directed mutagenesis and overlaps with the AR3C epitope. The x-ray and electron microscopy E2 structuresmore »« less
https://doi.org/10.1126/science.1243876
Computational identification of HCV neutralizing antibodies with a common HCDR3 disulfide bond motif in the antibody repertoires of infected individuals

Journal Article Bozhanova, Nina; Flyak, Andrew; Brown, Benjamin; ... - Nature Communications

Despite recent success in hepatitis C virus (HCV) treatment using antivirals, an HCV vaccine is still needed to prevent reinfections in treated patients, to avert the emergence of drug-resistant strains, and to provide protection for people with no access to the antiviral therapeutics. The early production of broadly neutralizing antibodies (bNAbs) associates with HCV clearance. Several potent bNAbs bind a conserved HCV glycoprotein E2 epitope using an unusual heavy chain complementarity determining region 3 (HCDR3) containing an intra-loop disulfide bond. Isolation of additional structurally-homologous bNAbs would facilitate the recognition of key determinants of such bNAbs and guide rational vaccine design.more »« less
https://doi.org/10.1038/s41467-022-30865-9

Full Text Available
A conserved epitope III on hepatitis C virus E2 protein has alternate conformations facilitating cell binding or virus neutralization

Journal Article Deng, Lu; Hernandez, Nancy; Zhong, Lilin; ... - Proceedings of the National Academy of Sciences of the United States of America

Epitope III, a highly conserved amino acid motif of ⁵²⁴APTYSW⁵²⁹ on the hepatitis C virus (HCV) E2 glycoprotein, resides in the critical loop that binds to the host receptor CD81, thus making it one of the most important antibody targets for blocking HCV infections. Here, we have determined the X-ray crystal structure of epitope III at a 2.0-Å resolution when it was captured by a site-specific neutralizing antibody, monoclonal antibody 1H8 (mAb1H8). The snapshot of this complex revealed that epitope III has a relatively rigid structure when confined in the binding grooves of mAb1H8, which confers the residue specificity atmore »« less
https://doi.org/10.1073/pnas.2104242118

Full Text Available

Similar Records